Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.

During 1979-1995, there was no vaccination against pertussis in Sweden. With the aim of studying the epidemiology and transmission of pertussis, mass vaccination with pertussis toxoid of children born during the 1990s was instituted in the Göteborg area (population, 778,597) in 1995. Infants were offered 3 doses of pertussis toxoid combined with diphtheria and tetanus toxoids. Children aged > or =1 year were offered 3 doses of pertussis toxoid alone. From June 1995 through February 1999, 167,810 doses of pertussis toxoid were given to 61,219 children born during the 1990s (56% received 3 doses). The number of Bordetella pertussis isolates per year declined from 1214 (1993-1995) to 64 (January 1997 through June 1999; P<.0001), and hospitalizations due to pertussis declined from 62 to 5 (P<.0001). Significant decreases in B. pertussis isolates and hospitalizations occurred in all age groups, including adults and nonvaccinated infants. Thus, mass vaccination of children with pertussis toxoid decreases spread of B. pertussis in the population.

[1]  A. Walker,et al.  The science and fiction of pertussis vaccines. , 2001, Pediatrics.

[2]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[3]  D Johnson,et al.  The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.

[4]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[5]  J. Gornbein,et al.  A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. , 1998, Vaccine.

[6]  M. Feinberg,et al.  Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5. , 1998 .

[7]  S. Hammer,et al.  Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1‐Infected Patients with 200–500 CD4 Cells/mm3(ACTG 175) , 1998, The Journal of Infectious Diseases.

[8]  S. Hammer,et al.  Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. , 1998, The Journal of infectious diseases.

[9]  R. Schneerson,et al.  Immunization of children with pertussis toxoid decreases spread of pertussis within the family. , 1998, The Pediatric infectious disease journal.

[10]  Ulrich Heininger,et al.  A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine , 1998, Pediatrics.

[11]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.

[12]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[13]  S. Mboup,et al.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. , 1997, Vaccine.

[14]  M. Hughes,et al.  Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.

[15]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[16]  L. Kalish,et al.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.

[17]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[18]  J. Bartlett,et al.  HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. , 1996, AIDS.

[19]  D. R. Kuritzkes,et al.  HIV viral load markers in clinical practice , 1996, Nature Medicine.

[20]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[21]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[22]  H. Hallander,et al.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.

[23]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[24]  M. Gahr,et al.  Efficacy of acellular pertussis vaccine in early childhood after household exposure. , 1996, JAMA.

[25]  H. Kawai,et al.  A causal relationship between Bordetella pertussis and Bordetella parapertussis infections. , 1996, Scandinavian journal of infectious diseases.

[26]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[27]  W. Blackwelder,et al.  Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. , 1995, Journal of immunological methods.

[28]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[29]  F. de Wolf,et al.  Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. , 1995, The Journal of infectious diseases.

[30]  J. Margolick,et al.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[31]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[32]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[33]  M. Pittman,et al.  Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine , 1993, The Pediatric infectious disease journal.

[34]  D. Richman,et al.  Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-point. , 1993, AIDS.

[35]  J. Taranger,et al.  How common is whooping cough in a nonvaccinating country? , 1993, The Pediatric infectious disease journal.

[36]  M. Osterholm,et al.  Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. , 1993, JAMA.

[37]  P E Fine,et al.  Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.

[38]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[39]  J. Cherry.  Pertussis: the trials and tribulations of old and new pertussis vaccines. , 1992, Vaccine.

[40]  C. Farrington,et al.  Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. , 1990, Vaccine.

[41]  I. Krantz,et al.  Estimating incidence of whooping cough over time: a cross-sectional recall study of four Swedish birth cohorts. , 1989, International journal of epidemiology.

[42]  S. Houard,et al.  Specific identification of Bordetella pertussis by the polymerase chain reaction. , 1989, Research in microbiology.

[43]  V. Romanus,et al.  Pertussis in Sweden after the cessation of general immunization in 1979. , 1987, The Pediatric infectious disease journal.

[44]  John R Murphy,et al.  STUDIES ON THE MOLECULAR EPIDEMIOLOGY OF DIPHTHERIA , 1983, The Lancet.

[45]  G. Guarini,et al.  STEATORRHŒA IN ADDISON'S DISEASE , 1963 .